Abstract
Introduction: Pretargeting parameters for use the anti-CEA (carcinoembryonic antigen) bispecific monoclonal antibody TF2 and the 68Ga-labeled IMP288 peptide (68Ga-IMP288) for Immuno-PET have been optimized in a first-in-human study performed in MTC (medullary thyroid carcinoma (MTC) patients (iPET-MTC study). The aim of this post-hoc analysis was to determine the sensitivity of Immuno-PET in relapsing MTC patients, in comparison with conventional imaging and 18F-DOPA PET/CT (DOPA-PET/CT). Methods: Twenty-five studies were analyzed in 22 patients. All patients received Immuno-PET 1-h and 2-h after 68Ga-IMP288 injection pretargeted by TF2, in addition to neck-thoracic-abdominal-pelvic computed tomography (CT), bone and liver magnetic resonance imaging (MRI), and DOPA-PET/CT. Gold standard (GS) was histology and/or confirmation by one other imaging method and/or imaging follow-up. Results: 190 lesions were confirmed by the GS: 89 in lymph nodes, 14 in lungs, 46 in liver, 37 in bone, and 4 in other sites (subcutaneous, heart, brain, and pancreas). 210 abnormal foci were detected by Immuno-PET. Among these, 174 (83%) were confirmed as true-positive by the GS. Immuno-PET showed a higher overall sensitivity (92%) than DOPA-PET/CT (65%). Regarding metastatic sites, Immuno-PET had a higher sensitivity than CT, DOPA-PET/CT or MRI for lymph nodes (98% vs 83% for CT and 70% for DOPA-PET/CT), liver (98% vs 87% for CT, 65% DOPA-PET/CT, and 89% for MRI) and bone (92% vs 64% for DOPA-PET/CT and 86% for MRI), whereas sensitivity was lower for lung metastases (29% vs 100% for CT and 14% for DOPA-PET/CT). Tumor SUVmax at 60 min ranged from 1.2 to 59.0 with intra- and inter-patient variability. Conclusion: This post-hoc study demonstrates that anti-CEA immuno-PET is an effective procedure for detecting metastatic MTC lesions. Immuno-PET showed a higher overall sensitivity than DOPA-PET/CT for disclosing metastases, except for the lung, where CT remains the most effective examination.
- Molecular Imaging
- Oncology: Endocrine
- Radioimmunoimaging
- Immuno-PET
- bispecific antibody
- carcinoembryonic antigen
- medullary thyroid cancer
- pretargeted radioimmunoimaging
- Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
SNMMI members
Login to the site using your SNMMI member credentials
Individuals
Login as an individual user